CL2007000161A1 - Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. - Google Patents

Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.

Info

Publication number
CL2007000161A1
CL2007000161A1 CL200700161A CL2007000161A CL2007000161A1 CL 2007000161 A1 CL2007000161 A1 CL 2007000161A1 CL 200700161 A CL200700161 A CL 200700161A CL 2007000161 A CL2007000161 A CL 2007000161A CL 2007000161 A1 CL2007000161 A1 CL 2007000161A1
Authority
CL
Chile
Prior art keywords
dioxoimidazolidine
kine
inhibitors
cancer
proteins
Prior art date
Application number
CL200700161A
Other languages
English (en)
Inventor
Frank Halley
Youssef El-Ahmad
Victor Certal
Corinne Venot
Anne Dagallier
Hartmut Strobel
Kurt Ritter
Sven Ruf
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CL2007000161A1 publication Critical patent/CL2007000161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200700161A 2006-01-23 2007-01-22 Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. CL2007000161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600566A FR2896503B1 (fr) 2006-01-23 2006-01-23 Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
CL2007000161A1 true CL2007000161A1 (es) 2008-05-30

Family

ID=36717140

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200700161A CL2007000161A1 (es) 2006-01-23 2007-01-22 Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.

Country Status (18)

Country Link
US (1) US20090082329A1 (es)
EP (1) EP2035408A1 (es)
JP (1) JP2009542586A (es)
KR (1) KR20080095860A (es)
AR (1) AR059085A1 (es)
AU (1) AU2007264848A1 (es)
BR (1) BRPI0710438A2 (es)
CA (1) CA2631506A1 (es)
CL (1) CL2007000161A1 (es)
EA (1) EA200870192A1 (es)
FR (1) FR2896503B1 (es)
IL (1) IL192440A0 (es)
MA (1) MA30225B1 (es)
NO (1) NO20082976L (es)
PE (1) PE20071112A1 (es)
TW (1) TW200738684A (es)
UY (1) UY30105A1 (es)
WO (1) WO2008000922A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3715391A1 (de) * 1987-05-08 1988-12-01 Gerhard Mederer Brennkraftmaschine oder sonstiger antrieb
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
BRPI0923527A2 (pt) * 2008-12-24 2016-08-09 Syngenta Ltd métodos de preparo de fungicidas
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
JP5442906B2 (ja) 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
US20170281641A1 (en) * 2014-09-03 2017-10-05 Genzyme Corporation CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
WO2016210036A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
PE20191817A1 (es) 2017-05-11 2019-12-27 Bristol Myers Squibb Co Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114127075B (zh) 2019-07-18 2024-05-14 百时美施贵宝公司 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021026181A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en) 2019-08-13 2026-03-24 Bristol Myers Squibb Co Bicyclic heteroaryl compounds useful as irak4 inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4100408B1 (en) 2020-02-03 2024-02-28 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
TW202517640A (zh) * 2023-07-18 2025-05-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Also Published As

Publication number Publication date
NO20082976L (no) 2008-09-10
KR20080095860A (ko) 2008-10-29
BRPI0710438A2 (pt) 2011-08-09
IL192440A0 (en) 2009-02-11
PE20071112A1 (es) 2007-12-13
TW200738684A (en) 2007-10-16
CA2631506A1 (fr) 2008-01-03
FR2896503B1 (fr) 2012-07-13
AR059085A1 (es) 2008-03-12
UY30105A1 (es) 2007-08-31
WO2008000922A1 (fr) 2008-01-03
MA30225B1 (fr) 2009-02-02
AU2007264848A1 (en) 2008-01-03
EA200870192A1 (ru) 2009-12-30
US20090082329A1 (en) 2009-03-26
JP2009542586A (ja) 2009-12-03
EP2035408A1 (fr) 2009-03-18
FR2896503A1 (fr) 2007-07-27

Similar Documents

Publication Publication Date Title
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2007002593A1 (es) Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000348A1 (es) Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.